Premium
Role of inflammation‐related gene polymorphisms in branch retinal vein occlusion
Author(s) -
WEGER M,
STEINBRUGGER I,
RENNER W,
MAIER R,
WEDRICH A,
SCHMUT O,
HAAS A
Publication year - 2009
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2009.2143.x
Subject(s) - branch retinal vein occlusion , interleukin 1 receptor antagonist , interleukin 10 , medicine , interleukin , genotype , single nucleotide polymorphism , proinflammatory cytokine , interleukin 8 , tumor necrosis factor alpha , immunology , inflammation , cytokine , gastroenterology , receptor , biology , receptor antagonist , gene , genetics , retinal , antagonist , ophthalmology , macular edema
Abstract Purpose Branch retinal vein occlusion (BRVO) is a common vision‐threatening disease. Some cytokines have previously been shown to exert proatherogenic as well as prothrombotic effects. Gene polymorphisms affecting the expression of these cytokines are thus plausible candidates as risk factors for BRVO. The purpose of the present study was to investigate hypothesized associations between cytokine gene polymorphisms and the presence of BRVO. Methods The present case‐control study comprised 398 patients with BRVO and 355 control subjects. Using 5`exonuclease assays (TaqMan), genotypes of the following single nucleotide polymorphisms were determined: interleukin 1 beta (IL1B) ‐511C>T, interleukin 1 receptor antagonist (IL1RN) 1018T>C, interleukin 4 (IL4) ‐584C>T, interleukin 6 (IL6) ‐174G>C, interleukin 10 (IL10) ‐592C>A, interleukin 18 (IL18) 183A>G, tumor necrosis factor (TNF) ‐308G>A, monocyte chemoattractant protein 1 (CCL2) ‐2518A>G, interleukin 8 (IL8) ‐251A>T and RANTES (CCL5) ‐403G>A. Results Neither genotype distributions nor allele frequencies of any of the investigated polymorphisms differed significantly between BRVO patients and control subjects (IL1B ‐511TT: 7.8% vs. 9.6%, p=0.68; IL1RN 1018CC: 12.1% vs. 13.5%, p=0.15, IL4 ‐584TT: 1.3% vs. 2.3%, p=0.58; IL6 ‐174CC: 17.8% vs.18.6%, p=0.97; IL10 ‐592AA: 5.3% vs. 9.0, p=0.14; IL18 183GG: 3.0 vs. 6.2%, p=0.11; TNF ‐308AA: 1.5% vs. 1.4%, p=0.95; CCL2 ‐2518GG: 6.5% vs. 4.5%, p=0.48; IL8 ‐251TT: 26.9% vs. 28.7%, p=0.23; CCL5 ‐403AA: 3.3% vs. 4.5%, p=0.63). Conclusion Our data suggest that none of the investigated cytokine gene polymorphisms is likely a major risk factor for BRVO.